BLISS GVS PHARMA LTD.

Bliss GVS Pharma Limited has announced the outcome of its Nomination and Remuneration Committee meeting held on August 12, 2026. The committee granted 3,20,000 stock options under the Bliss GVS Pharma Limited – Employee Stock Options Plan 2019 to eligible employees. These options are convertible into equity shares of Re. 1/- face value each. The exercise price is set at ₹43 per option, determined by the BSE last closing market price on August 11, 2026, with a 91.32% discount applied for uniformity. The options will vest in four installments over 48 months, with a minimum one-year period between grant and vesting. The exercise period is six months from vesting, and vested shares will be subject to a six-month lock-in post-allotment.

Bliss GVS Pharma Ltd announced that its Board of Directors met on August 12, 2026, to approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The board also approved a draft postal ballot notice for the appointment of Mr. Santosh Parab as a Non-Executive Non-Independent Director. The meeting was conducted via Video Conferencing/Other Audio Visual Means.

Bliss GVS Pharma Ltd announced that its Board of Directors met on August 12, 2026, to approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The board also approved a draft postal ballot notice for the appointment of Mr. Santosh Parab as a Non-Executive Non-Independent Director. The meeting was conducted via Video Conferencing.

Life Insurance Corporation of India (LIC) has filed a disclosure under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, revealing its shareholding in Bliss GVS Pharma Ltd. LIC currently holds 5.110% of the total share capital, amounting to 5,276,355 shares. The disclosure details a recent acquisition/sale of 2,132,071 shares, representing 2.151% of the diluted share capital, which occurred between September 9, 2020, and August 10, 2026, via market sale. Following this transaction, LIC's holding stands at 3,144,284 shares, representing 2.959% of the diluted share capital. The total equity share capital of Bliss GVS Pharma remains at 10,62,43,972.00.

Bliss GVS Pharma Ltd has announced that its Board of Directors will convene on August 12, 2026, to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. In line with SEBI regulations, the company has also closed its trading window for designated persons and their immediate relatives from July 01, 2026, until 48 hours after the financial results are announced. This information is available on the company's website.

SBI Capital Markets Ltd, acting as the Manager to the Open Offer for Bliss GVS Pharma Limited, has submitted a Pre-Offer Advertisement to the BSE. This advertisement is in accordance with Regulation 18(7) of the SEBI (SAST) Regulations, 2011. The open offer is being made by Anupam Rasayan India Limited, along with Mates Visa Consultancy Private Limited (PAC), to acquire up to 26.00% of the expanded voting share capital from eligible public shareholders. The detailed public statement was made on May 30, 2026, following a public announcement on May 23, 2026. The Pre-Offer Advertisement was published in newspapers on July 27, 2026.

Bliss GVS Pharma Limited's Committee of Independent Directors (IDC) has issued recommendations regarding an open offer made by Anupam Rasayan India Limited and Mates Visa Consultancy Private Limited. The offer aims to acquire up to 2,77,26,848 equity shares, representing 26.00% of the expanded voting share capital, at a price of INR 299.00 per share. The total offer size is INR 829,03,27,552.00. The IDC, comprising Mr. Nandkumar Kashinath Chodankar (Chairperson), Ms. Shilpa Vinodkumar Bhatia, Mr. Vijayanarayanan Mahadevan, and Mr. Deepak Rameshchandra Shah, has provided their reasoned recommendations as per SEBI (SAST) Regulations. All IDC members are independent directors, with only the Chairperson holding a nominal 250 equity shares in the target company.

Bliss GVS Pharma Ltd has announced that Clarus Capital I, along with its associated schemes (Clarus Capital I - LVF 1 and Clarus Capital 1 - LVF 2), collectively referred to as the 'Acquirer', has acquired a 5.13% stake in the company. This acquisition, managed by ChrysCapital Associates LLP, involved the purchase of 1,84,652 equity shares through open market transactions. The total holding of the Acquirer and its persons acting in concert (PAC), including ClearEdge LLC, now stands at 54,38,523 shares, crossing the 5% threshold as per SEBI's Takeover Regulations. The acquisition was completed on July 20, 2026, with the shares having a face value of Rs. 1/- each.

Bliss GVS Pharma Limited has received a Letter of Offer dated July 18, 2026, from SBI Capital Markets Limited, the manager to the Open Offer. Anupam Rasayan India Limited, along with Mates Visa Consultancy Private Limited (PAC), is making a cash offer to acquire up to 2,77,26,848 equity shares of Bliss GVS Pharma Limited. This represents 26.00% of the expanded voting share capital at an offer price of ₹299.00 per equity share. The offer is being made in compliance with SEBI (SAST) Regulations, 2011.

Bliss GVS Pharma Limited has received an addendum to the public announcement and detailed public statement regarding an open offer. The original offer was made by Anupam Rasayan Limited, the acquirer, for the acquisition of up to 26.00% of the expanded voting share capital of Bliss GVS Pharma Limited from eligible public shareholders. This addendum introduces Mates Visa Consultancy Private Limited as a person acting in concert (PAC) with the acquirer. The open offer is being made in compliance with SEBI (SAST) Regulations, 2011. The addendum was dated July 17, 2026, and has been shared with BSE and NSE.